Market Overview:
The global opioid induced constipation treatment market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic pain, rising geriatric population, and growing demand for opioids. In addition, the increasing awareness about opioid induced constipation (OIC) and its treatment options is also contributing to the growth of this market. Based on type, the global opioid induced constipation treatment market can be segmented into oral and parenteral (subcutaneous injection). Oral medications are currently dominating the global opioid induced constipation treatment market owing to their easy availability and low cost as compared to other treatments available for OIC. However, parenteral medications are expected to witness higher growth during the forecast period due to their high efficacy in treating OIC. Based on application, the global opioid induced constipation treatment market can be segmented into drug stores and hospital pharmacies. Drug stores currently dominate this market owing to their wide distribution network across regions worldwide coupled with easy access for consumers seeking relief from OIC symptoms.
Product Definition:
Opioid-induced constipation (OIC) is a common side effect of opioid pain medications. OIC is caused by the slowing of intestinal motility and can lead to abdominal pain, bloating, and constipation. Treatment for OIC includes increasing fluid intake, exercise, and dietary changes. Laxatives may also be prescribed to help relieve symptoms.
Oral:
Oral Opioid Induced Constipation (OIIC) is a condition wherein the usage of oral opioids, such as codeine, morphine and oxycodone for pain management leads to soft stooling. The condition is also known as opioid-induced constipation (OIC). It’s a clinical syndrome that affects the bowel movement and causes abdominal pain along with diarrhea or constipation.
Parenteral (Subcutaneous Injection):
Parenteral (Subcutaneous Injection) is a type of drug delivery system that involves directly injecting the drug into the intended tissue or body part. The most common parenteral injections are for insulin, antibiotics, chemotherapy drugs and anesthetic agents. Parenteral injections can be administered through a needle by using syringes or vials.
Application Insights:
Based on the application, the global market is segmented into drug store and hospital pharmacies. Drug stores are anticipated to dominate the market throughout the forecast period owing to growing awareness about online shopping among consumers. Furthermore, increasing number of retail outlets in countries such as India and China has also played a key role in driving growth for this segment.
Hospital pharmacies are expected to witness significant growth over the forecast period due to rising prevalence of chronic diseases such as cancer and heart conditions that require long-term treatment with strong opioids which cause constipation as a side effect. In addition, an increase in healthcare infrastructure coupled with growing awareness about opioid induced constipation treatment is further expected fuel demand from hospital pharmacies during future years.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing cases of opioid-related disorders, rising awareness about OIC treatment options, and availability of a large number of OIC treatment options.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to high unmet medical needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Moreover, growing demand for pain management therapy due to increasing prevalence of chronic diseases will drive regional market growth during the estimated time span.
Growth Factors:
- Increasing incidence of opioid induced constipation
- Growing awareness about the treatment for opioid induced constipation
- Rising demand for effective and safe treatments for opioid induced constipation
- Availability of novel therapies and drugs for the treatment of opioid induced constipation
- increasing research and development activities to develop better therapies for the treatment of opioid induced constipation
Scope Of The Report
Report Attributes
Report Details
Report Title
Opioid Induced Constipation Treatment Market Research Report
By Type
Oral, Parenteral (Subcutaneous Injection)
By Application
Drug Store, Hospital Pharmacies
By Companies
GlaxoSmithKline, AstraZeneca, Pfizer, S.L.A. Pharma, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Takeda Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
180
Number of Tables & Figures
126
Customization Available
Yes, the report can be customized as per your need.
Global Opioid Induced Constipation Treatment Market Report Segments:
The global Opioid Induced Constipation Treatment market is segmented on the basis of:
Types
Oral, Parenteral (Subcutaneous Injection)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Drug Store, Hospital Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- AstraZeneca
- Pfizer
- S.L.A. Pharma
- AIKO Biotechnology
- Cubist Pharmaceuticals
- Salix Pharmaceuticals
- Takeda Pharmaceutical
Highlights of The Opioid Induced Constipation Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Oral
- Parenteral (Subcutaneous Injection)
- By Application:
- Drug Store
- Hospital Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Opioid Induced Constipation Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Opioid induced constipation treatment is a medical procedure used to treat opioid-induced constipation. It involves the use of medications, such as laxatives, to help relieve the symptoms of constipation.
Some of the major companies in the opioid induced constipation treatment market are GlaxoSmithKline, AstraZeneca, Pfizer, S.L.A. Pharma, AIKO Biotechnology, Cubist Pharmaceuticals, Salix Pharmaceuticals, Takeda Pharmaceutical.
The opioid induced constipation treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Opioid Induced Constipation Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Opioid Induced Constipation Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Opioid Induced Constipation Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Opioid Induced Constipation Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Opioid Induced Constipation Treatment Market Size & Forecast, 2020-2028
4.5.1 Opioid Induced Constipation Treatment Market Size and Y-o-Y Growth
4.5.2 Opioid Induced Constipation Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Oral
5.2.2 Parenteral (Subcutaneous Injection)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Drug Store
6.2.2 Hospital Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Opioid Induced Constipation Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Opioid Induced Constipation Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Oral
9.6.2 Parenteral (Subcutaneous Injection)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Drug Store
9.10.2 Hospital Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Oral
10.6.2 Parenteral (Subcutaneous Injection)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Drug Store
10.10.2 Hospital Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Oral
11.6.2 Parenteral (Subcutaneous Injection)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Drug Store
11.10.2 Hospital Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Oral
12.6.2 Parenteral (Subcutaneous Injection)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Drug Store
12.10.2 Hospital Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Oral
13.6.2 Parenteral (Subcutaneous Injection)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Drug Store
13.10.2 Hospital Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Opioid Induced Constipation Treatment Market: Competitive Dashboard
14.2 Global Opioid Induced Constipation Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GlaxoSmithKline
14.3.2 AstraZeneca
14.3.3 Pfizer
14.3.4 S.L.A. Pharma
14.3.5 AIKO Biotechnology
14.3.6 Cubist Pharmaceuticals
14.3.7 Salix Pharmaceuticals
14.3.8 Takeda Pharmaceutical
